Meanwhile, these findings suggested that its role as a biomarker was particularly significant in certain cancers, such as lung cancer and melanoma, where high PLEK2 levels correlate strongly with poorer clinical outcomes and reduced immunotherapy response. The gene discussed is PLEK2; the disease is lung carcinoma.